Skip to main content

RARE

Stock
Health Care
Biotechnology

Performance overview

RARE Price
Price Chart

Forward-looking statistics

Beta
1.09
Risk
40.23%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Company info

SectorHealth Care
IndustryBiotechnology
Employees1K
Market cap$3.4B

Fundamentals

Enterprise value$3.8B
Revenue$590.7M
Revenue per employee—
Profit margin-93.04%
Debt to equity588.24

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$5.83
Dividend per share—
Revenue per share$6.32
Avg trading volume (30 day)$31M
Avg trading volume (10 day)$30M
Put-call ratio—

Macro factor sensitivity

Growth-2.2
Credit+8.0
Liquidity+2.8
Inflation-4.7
Commodities-2.8
Interest Rates-2.2

Valuation

Dividend yield0.00%
PEG Ratio-7.81
Price to sales6.39
P/E Ratio-7.81
Enterprise Value to Revenue6.49
Price to book25.93

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day—
Ex. dividend day—

News

RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End

Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.

Zacks Investment Research (July 10, 2025)
Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains?

Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Investment Research (July 10, 2025)
Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win

Ultragenyx Pharmaceutical Inc. RARE and Mereo BioPharma Group plc MREO stocks are plunging on Thursday.

Benzinga (July 10, 2025)
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday.

Benzinga (July 10, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free